Micro-laminin gene therapy can function as an inhibitor of muscle disease in the dy mouse model of MDC1A.

Gene replacement for laminin-α2-deficient congenital muscular dystrophy 1A (MDC1A) is currently not possible using a single adeno-associated virus (AAV) vector due to the large size of the gene. encodes laminin-α2, a subunit of the trimeric laminin-211 extracellular matrix (ECM) protein that is the predominant laminin expressed in skeletal muscle. expression stabilizes skeletal muscle, in part by binding membrane receptors via its five globular (G) domains. We created a small, AAV-deliverable, micro-laminin gene therapy that expresses these G1-5 domains, , to test their therapeutic efficacy in the dy mouse model for MDC1A. We also fused the heparin-binding (HB) domain from HB epidermal growth factor-like growth factor (HB-EGF) to to test whether this would increase muscle ECM expression. dy mice treated intravenously with rAAV9.CMV. showed increased muscle ECM expression of transgenic protein relative to mice treated with rAAV9.CMV. and showed improved weight-normalized forelimb grip strength relative to untreated dy mice. Additionally, dy muscle fibers expressing either micro-laminin protein showed some measures of reduced pathology, although levels of muscle cell apoptosis and inflammation were not decreased. Although systemic expression of rAAV9.CMV. did not inhibit all disease phenotypes, these studies demonstrate the feasibility of using a micro-laminin gene therapy strategy to deliver gene replacement for MDC1A.